Pay in 4 interest-free payments of $5.93 Learn more
Ships within 48 hours · Estimated delivery Sep 18 - Sep 23
The FDA approved Zepbound (tirzepatide for obesity) on November 8, 2023 [2], meaning it entered the obesity-specific reimbursement field only recently
This extended action is one reason healthcare professionals recommend keeping injections on the same day each week for consistency
Can I appeal a GLP-1 medication denial
doi: 10.1016/j.ccl.2013.09.002 19 TsukamotoOKitakazeM
[1] [2] Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist with similar clinical effects
US$ 29.66
US$ 20.82
US$ 29.70
US$ 27.11
US$ 21.61
US$ 21.63
US$ 26.37
US$ 29.72
US$ 26.54
US$ 23.09
